Informações: Esta não é a versão mais recente do modelo de dados. Uma visão geral da versão pode ser encontrada à esquerda em Versões. Para a versão mais recente, clique aqui.
Informações:
Falhas:
ID
34574
Descrição
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02454179
Link
https://clinicaltrials.gov/show/NCT02454179
Palavras-chave
Versões (2)
- 19/01/2019 19/01/2019 -
- 28/05/2021 28/05/2021 -
Titular dos direitos
see on clinicaltrials.gov
Transferido a
19 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Squamous Cell Carcinoma of the Head and Neck NCT02454179
Eligibility Squamous Cell Carcinoma of the Head and Neck NCT02454179
- StudyEvent: Eligibility
Similar models
Eligibility Squamous Cell Carcinoma of the Head and Neck NCT02454179
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
men and women ≥ 18 years of age
boolean
ID.2
Item
histologically or cytologically confirmed recurrent, metastatic or unresectable hnscc of the oral cavity, oropharynx, hypopharynx, and larynx that that has either progressed during or after platinum-based chemotherapy administered for metastatic disease or has recurred during or within 6 months after the completion of platinum-based neoadjuvant or adjuvant therapy
boolean
ID.3
Item
presence of radiographically measurable disease as defined by recist 1.1
boolean
ID.4
Item
ecog performance status of 0 or 1
boolean
ID.5
Item
prior malignancy (other than hnscc), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to < 2 years
boolean
ID.6
Item
known central nervous system metastases and/or carcinomatous meningitis
boolean
ID.7
Item
a life-threatening illness, medical condition (including psychiatric conditions) or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety
boolean
ID.8
Item
significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of starting study drug
boolean